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OBJECTIVES The aim of this study was to determine the natural history of patients with hypertrophic
cardiomyopathy (HCM) and severe left ventricular hypertrophy (LVH) (i.e., maximal left
ventricular wall thickness [MLVWT] 30 mm) and whether changes in cardiac morphology
influence the course of the disease.
BACKGROUND Severe LVH is common in young and rare among elderly patients with HCM. This has been
explained by a high incidence of sudden death. We hypothesized that this age-related
difference might be explained by left ventricular wall thinning.
METHODS A total of 106 (age 33 15 years; 71 males) consecutive patients with severe LVH underwent
history taking, examination, electrocardiography, echocardiography, cardiopulmonary exer-
cise testing, and Holter analysis. Survival data were collected at subsequent clinic visits or by
communication with patients and their general practioners. In order to assess morphologic
and functional changes, 71 (67.0%) patients (mean age 31  15 years; 47 males) followed at
our institution underwent serial (1 year) assessment.
RESULTS Of the 106 patients, the majority (78 [71.6%]) were 40 years of age. During follow-up (92 
50 months [range 1 to 169]), 18 (17.0%) patients died or underwent heart transplantation (13
sudden cardiac deaths, 2 heart failure deaths, 1 heart transplantation, 1 stroke, 1 postoperative
death). Five-year survival from sudden death was 90.1% (95% confidence interval [CI] 84.0% to
96.3%), and that from heart failure death or transplantation was 97.7% (95% CI 94.5 to 100). In
patients serially evaluated over 85  51 months, there was an overall reduction in MLVWT of
0.6 mm/year (95% CI 0.31 to 0.81, p  0.00004). Wall thinning 5 mm was observed in 41
patients (57.7%; age 35  13 years; 28 males). On multivariate analysis, the follow-up duration
only predicted wall thinning (0.6 mm/year, 95% CI 0.38 to 0.85, p  0.00001).
CONCLUSIONS Left ventricular remodeling is common in patients with severe LVH and contributes to the
low prevalence of severe LVH seen in middle age and beyond. (J Am Coll Cardiol 2004;
44:398–405) © 2004 by the American College of Cardiology Foundationt
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Gypertrophic cardiomyopathy (HCM) is an inherited car-
iac condition characterized by unexplained myocardial
ypertrophy. Approximately 10% of patients have severe left
entricular hypertrophy (LVH), defined as maximal left
entricular wall thickness (MLVWT) of 30 mm or more
1,2). Recent studies have indicated that this level of
See page 406
ypertrophy is relatively common in young patients and rare
mong elderly patients (1–4). The suggested explanation for
From the Department of Cardiological Sciences, St. George’s Hospital Medical
chool, London; and The Heart Hospital, University College London, London,
nited Kingdom. Dr. Thaman, Dr. Tome Esteban, and Prof. McKenna were
upported by the British Heart Foundation; Dr. Murphy by the Irish Heart
oundation/Novatis; and Dr. Gimeno by the Cardiovascular Research Foundation of
urcia (Spain).
Manuscript received July 24, 2003; revised manuscript received January 21, 2004,1ccepted January 27, 2004.hese age-related differences is that young patients with
evere LVH do not survive into middle age and beyond
ecause of the high incidence of sudden cardiac death (1).
n alternative explanation is that patients with severe LVH
ndergo left ventricular (LV) wall thinning.
The aims of this study were to investigate the natural
istory of patients with severe LVH by using serial M-mode
nd two-dimensional echocardiography and to determine
hether changes in cardiac morphology can explain the low
revalence of severe LVH in elderly patients.
ETHODS
atients. The study cohort consisted of 106 consecutive
atients (mean age 33  15 years; 71 males and 35 females)
ith HCM and severe LVH (30 mm on two-dimensional
chocardiography), who were assessed prospectively at St.
eorge’s Hospital, London, United Kingdom, between988 and 2002. Patients with other cardiac or systemic
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July 21, 2004:398–405 Severe Hypertrophy in HCMiseases known to produce hypertrophy, such as hyperten-
ion, aortic valve disease, and metabolic or storage disorders
e.g., Anderson Fabry disease and glycogen storage disease)
ere excluded. Hypertrophic cardiomyopathy was diag-
osed after successful resuscitation from an out-of-hospital
ardiac arrest in 2 patients (1.9%), after presentation with
ymptoms in 58 (54.7%), and during familial assessment in
8 (17.0%). The diagnosis was an incidental finding in 28
atients (26.4%). The reasons for referral to St. George’s
ospital were clinical management (44 [41.5%]), risk strat-
fication (24 [22.6%]), family screening (12 [11.3%]), diag-
ostic clarification (3 [2.8%]), and genetic counseling or
eferral for a second opinion (23 [21.7%]).
linical evaluation. Patients were entered into the study at
he time that severe LVH (MLVWT 30 mm) was first
ecorded by echocardiography. All patients underwent a
istory, examination, 12-lead electrocardiography, echocar-
iography, cardiopulmonary exercise testing with measure-
ent of blood pressure response, and 48-h Holter analysis
t the initial evaluation. Patients also underwent risk strat-
fication; severe LVH was considered a risk marker for
udden cardiac death (1,2), along with nonsustained ven-
ricular tachycardia (NSVT, defined as one or more runs of
or more consecutive ventricular extrasystoles at a rate of
120 beats/min, lasting for 30 s [4,5]), abnormal blood
ressure response during upright exercise (failure of systolic
lood pressure to rise by 25 mm Hg from baseline values,
r a fall of 10 mm Hg from the maximal blood pressure
uring upright exercise in patients under the age of 40 years
4,6,7]), family history of sudden cardiac death (8,9), and
nexplained syncope (9).
chocardiography. Two-dimensional, M-mode, and Dopp-
er echocardiography were performed using Acuson 128
P/10 (Mountain View, California), GE Vingmed System
(GE Ultrasound Europe, Horten, Norway), or Hewlett-
ackard Sonos 1000 (Hewlett-Packard, Andover, Massa-
husetts). The magnitude and distribution of LVH were
ssessed in the parasternal short-axis view and confirmed
rom the parasternal long-axis and apical views. The ven-
ricle was divided into four regions: anterior septum, pos-
erior septum, lateral wall, and posterior walls. Wall thick-
ess was measured at the level of the mitral valve and
Abbreviations and Acronyms
FS  fractional shortening
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LV  left ventricular
LVEDD  left ventricular end-diastolic diameter
LVESD  left ventricular end-systolic diameter
LVH  left ventricular hypertrophy
LVOTG  left ventricular outflow tract gradient
MLVWT  maximal left ventricular wall thickness
NSVT  nonsustained ventricular tachycardiaapillary muscles in each of the four myocardial segments Ind at the apical level in the anterior and posterior seg-
ents. The MLVWT was defined as the greatest thickness
n any segment. Patterns of hypertrophy were defined in
ccordance with previously published methods. Left ven-
ricular end-diastolic diameter (LVEDD) and left ventric-
lar end-systolic diameter (LVESD) were measured from
wo-dimensional and M-mode images obtained from the
arasternal long-axis views and percent fractional shorten-
ng (%FS), calculated using the formula: FS  ([LVEDD
LVESD]/LVEDD)  100. Systolic impairment was
efined as FS  25%. The left ventricular outflow tract
radient (LVOTG) was calculated from continuous wave
oppler imaging, using the modified Bernoulli equation:
P  4V2, where P is the instantaneous pressure gradient
mm Hg) and V is the measured maximal flow velocity
m/s). An LVOTG30 mm Hg was considered significant
10).
All images were stored on 5-inch videotape and reviewed
ndependently by two experienced investigators. The mean
f three measurements was taken for each segment or
iameter. A third experienced echocardiographer was asked
o adjudicate when there was a discrepancy of more than
0%. Differences between observers occurred in 5% of
ases and were2 mm; a consensus value was reached in all
ases.
urvival analysis. Data on survival and clinical status were
ollected at subsequent clinic visits in those patients fol-
owed up at our institution and by direct communication
ith patients and their general practitioners when followed
lsewhere.
End points for survival analysis were: 1) sudden cardiac
eath: witnessed sudden death with or without documented
entricular fibrillation, death within 1 h of new symptoms,
r nocturnal death with no antecedent history of worsening
ymptoms; 2) progressive heart failure death: death pre-
eded by signs and symptoms of heart failure or cardiogenic
hock; 3) other cardiovascular death: deaths due to stroke,
ulmonary or systemic embolism, and myocardial infarc-
ion; 4) noncardiovascular death: deaths caused by known
oncardiovascular events; and 5) orthotopic heart transplan-
ation.
erial evaluation. To assess morphologic and functional
hanges, patients followed at our institution underwent
erial (at least 2, 1 or more years apart) echocardiographic
nd clinical assessment. Patients who underwent myectomy
n  1) or alcohol septal ablation (n  1) or who had not
ompleted 12 months of follow-up (n  17) were excluded
rom this part of the study. Patients with typical angina or
isk factors for coronary artery disease underwent coronary
rteriography, and one patient with coronary artery disease
as also excluded. The results of serial evaluation in the
emaining 71 patients (67.0%; mean age 31  15 years; 47
ales and 24 females) are reported.
tatistical analysis. Statistical analysis was performed using
PSS statistical software (version 10.0; SPSS Inc., Chicago,
llinois). All data are expressed as the mean value  SD or
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Severe Hypertrophy in HCM July 21, 2004:398–405requency (percentage). Differences between mean values were
etermined using the unpaired or paired Student t test, where
ppropriate. The chi-square test was used for comparisons
etween dichotomous variables. Survival estimates were calcu-
ated by the Kaplan-Meier method, and their relation to
hanges in left ventricular wall thickness was tested by log-
ank. Five-year survival values are expressed together with their
5% confidence interval (CI), defined as survival 1.96 SE.
ox regression analysis was used to investigate the relationship
etween significant variables, survival, and changes in
LVWT.
Patients who underwent serial evaluation were classified
nto three groups based on changes in MLVWT: 5 mm
eduction (group 1); 2 to 4 mm reduction (group 2); and no
hange (2 mm reduction or increase) in MLVWT (group
). For statistical purposes, comparisons were made between
atients from group 1 and patients with lesser degrees or no
all thinning (i.e., groups 2 and 3). Two patients who had
n increase in MLVWT 2 mm were included in group 3
or statistical analysis. The relationship between a change in
LVWT (as a continuous variable) and other clinical
ariables was also investigated by using linear regression
nalysis. A p value 0.05 was considered statistically sig-
ificant.
ESULTS
nitial evaluation. The results of the initial clinical assess-
ent in the 106 patients with severe LVH are shown in
able 1. The majority (n  78 [71.6%]) of patients studied
ere less than 40 years of age (Fig. 1). The mean MLVWT
as 32  3 mm (range 30 to 45); 87 patients (90.6%) had
symmetric septal hypertrophy, 8 (8.3%) had concentric
ypertrophy, and 1 (1.0%) had apical hypertrophy. No
atient had FS 25%. Thirty-four patients (32.1%) had a
ignificant resting LVOTG, and 60 patients (57.0 %) had
eft atrial enlargement (40 mm). Five patients (4.7%) were
n atrial fibrillation, 3 (2.8%) had a DDDR pacemaker (for
reatment of outflow tract obstruction), and 2 (1.9%) had an
mplantable cardioverter-defibrillator (ICD; 1 for primary
nd 1 for secondary prevention). The presence or absence of
ymptoms and other clinical variables at the initial evalua-
ion are shown in Table 1.
urvival. Follow-up was complete in 103 patients
97.2%), and the mean follow-up time was 92  50
onths (range 1 to 169). During this time, 14 patients
nderwent ICD implantation (11 for primary and 3 for
econdary prevention) and 10 patients (9.4%) required a
acemaker (4 for treatment of symptomatic outflow tract
bstruction, 4 for conduction disease, 1 for chronotropic
ncompetence, and 1 for treatment optimization). Eigh-
een patients (17.0%) died or underwent orthotopic heart
ransplantation (13 sudden cardiac deaths, 2 heart failure–
elated deaths, 1 heart transplantation, 1 stroke-related
eath, 1 postoperative death). None of the 14 patients
ith ICDs experienced a device discharge. The five-year mumulative survival rate from sudden cardiac death was
0.1% (95% CI 84.0 to 96.3); the five-year cumulative
urvival rate from heart failure death or transplantation
as 97.7% (95% CI 94.5 to 100); and the five-year
umulative survival rate from all-cause mortality and
ransplantation was 86.8% (95% CI 79.8 to 93.8) (Fig. 2).
he majority of patients (8 [66.6%]) who died were
ounger than the age of 30 years. There was a significant
ssociation between survival from sudden death and the
umber of risk markers present. Twelve (85.7%) of the 13
atients who died suddenly had one or more additional
ecognized risk markers; the five-year survival rate from
udden death in patients with one or more additional risk
arkers was 87.4% (95% CI 79.2 to 95.7), as compared
ith 96.5% (95% CI 89.7 to 100; p  0.07 by log-rank)
n patients with severe LVH and no other recognized risk
able 1. Baseline Characteristics of Study (n  106) Patients
ale/female 71/35
ge (yrs) 33  15
ge at diagnosis (yrs) 28  16
linical follow-up (months) 92  50
F 2 (1.9%)
F 5 (4.7%)
xertional chest pain 32 (30.5%)
YHA dyspnea class
I 66 (62.3%)
II 37 (34.9%)
III/IV 4 (3.8%)
HSCD 31 (29.2%)
HHCM 43 (57.3%)
yncope 23 (21.9%)
BPR 38 (40.9%)
SVT 17 (17.2%)
attern
ASH 87 (90.6%)
Concentric 8 (8.3%)
Apical 1 (1.0%)
LVWT (mm) 32.1  3.0
VEDD (mm) 38.5  5.7
VESD (mm) 20.3  4.9
S (%) 47.1  10.2
AD (mm) 42.2  8.1
VOTG 34 (32.1%)
R
Moderate 3 (2.8%)
Severe 0
O2 max (%) 63.8  16.8
edication taken during follow-up
Beta-blocker 51 (48.1%)
Calcium antagonist 37 (34.9%)
ACE inhibitor 8 (7.5%)
ata are presented as the mean value  SD or number (%) of patients.
ABPR  abnormal blood pressure response during upright exercise; ACE 
ngiotensin-converting enzyme; AF  atrial fibrillation; ASH  asymmetric septal
ypertrophy; FHHCM family history of hypertrophic cardiomyopathy; FHSCD
amily history of sudden cardiac death; FS  fractional shortening; LAD  left atrial
iameter; LVEDD  left ventricular end-diastolic diameter; LVESD  left
entricular end-systolic diameter; LVOTG  left ventricular outflow tract gradient
30 mm Hg); MLVWT  maximal left ventricular wall thickness; MR  mitral
egurgitation; NSVT  nonsustained ventricular tachycardia; NYHA  New York
eart Association; VF  ventricular fibrillation; %VO2 max  %predicted maximal
xygen consumption during upright exercise.arkers (Fig. 3).
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July 21, 2004:398–405 Severe Hypertrophy in HCMesults of serial evaluation. The mean follow-up time in
he 71 patients who underwent serial clinical and echocar-
iographic evaluation was 85  51 months (range 12 to
86). In these patients, there was a decrease in MLVWT
rom 32  3 to 27  5 mm, corresponding to a reduction
n MLVWT of 0.6 mm/year (95% CI 0.31 to 0.81, p 
.00004). At final follow-up, only 23 patients (32%) had
Figure 1. Age distribution of the 106 patients studied and sigure 2. Kaplan-Meier survival estimates free from sudden cardiac death, hearLVWT 30 mm. Changes in maximal wall thickness in
he different myocardial segments are shown in Table 2.
Wall thinning of 5 mm or more was observed in 41
atients (57.7%; age 35  13 years; 28 males and 13
emales), of whom 35 (85.4%) had asymmetric septal
ypertrophy, 5 (12.2%) had concentric hypertrophy, and 1
2.4%) had apical hypertrophy. Wall thinning occurred
death (darker shading in bars represents sudden deaths).t failure/transplantation, and all-cause mortality in the study population.
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Severe Hypertrophy in HCM July 21, 2004:398–405redominantly in the anterior septum at the level of the
itral valve and papillary muscle and was accompanied by
n increase in LV cavity size (from 38.4 5.0 to 44.6 6.8
m for LVEDD [p  0.00001] and from 20.7  5.0 to
6.7  7.9 mm for LVESD [p  0.00001]), left atrial size
Figure 3. Kaplan-Meier survival estimates free from sudden cardiac death
able 2. Changes in Echocardiographic Measurements During
ollow-Up
Mean  SD
95% CI
p Value*Lower Upper
VEDD (mm) 5.5  6.6 7.1 4.0 0.00001
VESD (mm) 5.0  6.8 6.6 3.4 0.00001
S (%) 3.9  11.9 1.1 6.7 0.008
AD (mm) 4.3  6.5 5.8 2.7 0.00001
LVWT (mm) 5.2  4.4 4.1 6.2 0.00001
itral valve
Anterior septum 3.8  4.5 2.7 4.8 0.00001
Posterior septum 2.6  4.6 1.5 3.7 0.00002
Posterior wall 0.5  2.8 0.2 1.2 0.1
Lateral wall 1.2  2.8 0.5 2.0 0.002
apillary muscle
Anterior septum 4.4  4.5 3.3 5.5 0.00001
Posterior septum 2.9  4.3 1.8 4.0 0.00001
Posterior wall 0.2  2.7 0.5 0.8 0.6
Lateral wall 1.1  3.2 0.3 2.0 0.01
pex
Anterior wall 1.5  3.8 0.5 2.6 0.005
Posterior wall 0.4  2.1 0.2 1.0 0.2
Two-tailed.
(CI  confidence interval; other abbreviations as in Table 1.from 43.0  8.1 to 47.7  7.9 mm, p  0.00001), and
eduction in FS (from 46.2  11.1% to 40.8  11.2%, p 
.01). Three patients (7.3%) progressed to systolic impair-
ent (FS 25%), and there was a reduction in the number
f patients with significant LVOTG (from 10 [24.4%] to 7
17.9%], p  0.05).
A reduction in MLVWT of 2 to 4 mm was observed in
5 patients (21.1%; age 30  16 years; 10 males and 5
emales), of whom 14 (93.3%) had asymmetric septal
ypertrophy and 1 (6.7%) had concentric hypertrophy.
all thinning also occurred predominantly in the ante-
ior septum at the level of the mitral valve and papillary
uscles. Left ventricular cavity size increased (from 37.8
5.8 to 43.7  3.6 mm [p  0.00001] for LVEDD and
rom 19.2  4.3 to 23.1  5.9 mm [p  0.02] for
VESD), and left atrial size increased (from 40.8  8.3
o 46.2  9.0 mm, p  0.0008). No significant change in
FS or the number of patients with significant LVOTG
as observed.
A minimal or no change in wall thickness (2 mm
eduction or increase) was observed in 13 patients (18.3%;
ge 23 16 years; 8 males and 5 females). In these patients,
mall but significant changes in cavity size (from 39.3  7.7
o 41.8  9.7 mm [p  0.4] for LVEDD and from 20.5 
.8 to 23.1 8.2 mm [p 0.1] for LVESD), left atrial size
from 38.8  9.4 to 40.9  9.4 mm, p  0.3), and %FS
tients with one or more risk factors. LVH  left ventricular hypertrophy.from 46.5  12.2% to 45.5  9.2%, p  0.6) were
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July 21, 2004:398–405 Severe Hypertrophy in HCMbserved. An increase in MLVWT of2 mm was observed
n two individuals (2.8%): MLVWT increased by 4 mm in
ne and by 5 mm in the other. These patients were 17 and
years old, respectively, at the initial evaluation, and the
hanges were not accompanied by any significant change in
avity size, left atrial size, or LVOTG.
linical characteristics and survival in patients serially
valuated. Age, gender, and other clinical features at the
nitial evaluation in the three groups of patients are shown
n Table 3. Patients with wall thinning of 5 mm were
lder (35 vs. 26 years old, p  0.02) and had a higher
revalence of NSVT (11 [26.8%] vs. 2 [6.7%], p  0.04) at
he initial evaluation, as compared with patients with lesser
mounts of wall thinning. There were no other differences
n baseline symptoms, clinical features, exercise capacity
percent maximal oxygen consumption), or medications
aken. Compared with the initial evaluation, no significant
hanges in symptoms, New York Heart Association func-
ional class, or exercise variables were observed during
Table 3. Differences in Baseline Clinical Chara
Thickness
>5 mm
Number (%) of patients 41 (57.7
Age (yrs) 35  1
Age (yrs) at diagnosis 29  1
Gender (male/female) 28/13
Echocardiographic follow-up (months) 90  4
FHSCD 13 (31.7
FHHCM 27 (65.9
NYHA class
I 24 (58.5
II 15 (36.6
III/IV 2 (4.9%
Exertional chest pain 14 (34.1
Syncope 9 (22.0
ABPR 18 (43.9
VO2 max (%) 66.0  1
NSVT 11 (26.8
LVEDD (mm) 38.4  5
LVESD (mm) 20.7  5
FS (%) 46.2  1
MLVWT (mm) 32.7  3
LAD (mm) 43.0  8
Pattern
ASH 35 (85.4
Concentric 5 (12.2
Apical 1 (2.4%
LVOTG (mm Hg)
MR 10 (24.4
Moderate 0
Severe 0
Medication taken during follow-up
Beta-blocker 17 (41.5
Calcium antagonist 17 (41.5
ACE inhibitor 7 (17.1
*Two patients who had increased MLVWT 4 and 5 mm are
with significant wall thinning and patients with mild or no c
patients or mean value  SD.
Abbreviations as in Table 1.ollow-up in the three groups. However, seven patients p17.1%) who underwent wall thinning of 5 mm were
ommenced on angiotensin-converting enzyme inhibitors
or symptoms of congestive cardiac failure or systolic dys-
unction, as compared with no patients with lesser amounts
f wall thinning. There were no other significant differences
n medications taken during follow-up.
There were no significant differences in survival be-
ween patients with 5 mm or lesser amounts of wall
hinning: five patients (12.2%) with wall thinning 5
m died (three sudden cardiac deaths, two heart failure
eaths), compared with five patients (16.7%; four sudden
ardiac deaths, one procedure-related death) with lesser
r no wall thinning. The five-year cumulative survival
ate from all-cause mortality was 83.8% (95% CI 69.2 to
8.5) for patients with 5 mm wall thinning, compared
ith 97.4% (95% CI 92.5 to 100) for patients without
ignificant wall thinning (p  0.2).
redictors of wall thinning. Patients who developed sig-
ificant wall thinning were older (35 13 vs. 26 16 years,
stics in Relation to Changes in Wall
ction
Change* <2 mm p Value†2–4 mm
15 (21.1%) 15 (21.1%)
30  16 22  12 0.02
24  14 16  13 0.01
10/5 9/6 0.7
61  50 39  31 0.0001
4 (26.7%) 1 (6.7%) 0.2
8 (53.3%) 2 (13.3%) 0.003
7 (46.7%) 11 (73.3%) 1
8 (53.3%) 3 (20.0%) 1
0 1 (6.7%) —
6 (40.0%) 2 (13.3%) 0.5
4 (26.7%) 1 (6.7%) 0.5
4 (26.7%) 7 (46.7%) 0.7
62.9  15.0 63.5  17.2 0.5
1 (6.7%) 1 (6.7%) 0.04
37.8  5.8 38.1  7.8 0.7
19.2  4.3 19.7  5.1 0.3
49.1  8.7 47.5  11.8 0.4
31.9  2.6 32.4  4.1 0.5
40.8  8.3 38.7  9.1 0.1
14 (93.3%) 15 (100%) 0.2
1 (6.7%) 0 0.4
0 0 —
2 (13.3%) 7 (46.7%) 0.9
1 (6.7%) 0 —
0 0 —
8 (53.3%) 11 (73.3%) 0.07
7 (46.7%) 4 (26.7%) 0.7
0 0 0.02
ded in this group. †Relates to comparison between patients
in wall thickness. Data are presented as the number (%) ofcteri
Redu
%)
3
6
1
%)
%)
%)
%)
)
%)
%)
%)
7.6
%)
.0
.0
1.1
.1
.1
%)
%)
)
%)
%)
%)
%)
inclu
hange 0.02), had a longer follow-up duration (90  41 vs. 50

f
p
t
d
m
p
D
T
t
P
p
m
o
W
v
l
p
c
(
a
M
m
k
l
i
n
p
s
s
l
m
p
P
n
d
t
b
t
s
r
C
t
p
s
a
l
g
p
m
g
p
r
S
t
m
w
t
a
a
s
o
m
o
t
m
c
c
t
i
h
o
p
a
i
n
e
t
t
t
C
p
p
R
d
o
R
H
U
R
404 Thaman et al. JACC Vol. 44, No. 2, 2004
Severe Hypertrophy in HCM July 21, 2004:398–40543 months, p  0.0002), and were more likely to have a
amily history of HCM (27 [65.9%] vs. 10 patients [33.3%],
 0.007) than patients with mild or no change in wall
hickness. Using multivariate analysis, only the follow-up
uration predicted the development of wall thinning (0.6
m reduction in MLVWT per year [95% CI 0.38 to 0.85],
 0.00001).
ISCUSSION
his study shows that wall thinning significantly contributes to
he lower incidence of severe LVH in middle and older age.
revious studies have reported wall thinning in up to 15% of
atients with HCM (11). In this study, wall thinning of 5
m occurred in nearly 60% of patients with severe LVH, and
nly 32% of patients had severe LVH at the final evaluation.
all thinning occurred predominantly at the anterior inter-
entricular septum at the mitral valve and papilliary muscle
evels (i.e., areas of maximal hypertrophy in the majority of
atients studied) and was accompanied by an increase in LV
avity size and a reduction in LVOTG and FS. Three patients
4.2%) progressed to “end-stage” disease with cavity dilation
nd severe systolic impairment.
echanisms responsible for LV wall thinning. The
echanisms responsible for remodeling in HCM are un-
nown. In dilated and ischemic cardiomyopathy, myocardial
oad or injury results in changes at the cellular, molecular, and
nterstitial levels. These changes include myocardial ischemia,
ecrosis, apoptosis, increased collagen synthesis, and fibroblast
roliferation and eventually result in alterations in the size,
hape, and function of the heart (12,12–25). It is likely that
imilar processes occur in HCM, modified by hemodynamic
oad, neurohormonal activation, oxidative stress, cytokines, and
yocardial ischemia, all of which may play a greater role in
atients with severe LVH (26–28).
redictors of wall thinning. On univariate analysis, sig-
ificant wall thinning was related to age and follow-up
uration. Wall thinning was more common in patients older
han the age of 40 years, and there was a linear correlation
etween the amount of wall thinning and follow-up dura-
ion. After correcting for age, only follow-up duration was
ignificantly related to wall thinning, suggesting that the
emodeling process is a time-related phenomenon.
linical implications of severe LVH and remodeling. In
his study, survival was related to the number of risk markers
resent, rather than to progressive thinning. Patients with
ignificant wall thinning did, however, have a higher prev-
lence of NSVT at baseline, compared with patients with
esser amounts or no wall thinning, possibly reflecting a
reater disruption of myocardial structure or fibrosis in these
atients. Although patients with wall thinning were no
ore likely to have a sudden cardiac death, they had a
reater tendency toward other adverse outcomes, including
rogression to severe systolic impairment and heart failure-
elated death.tudy limitations. The main limitation to this study was
hat we were unable to study patients independently of
edication; however, this is one of the inherent difficulties
hen performing studies of this nature. In patients receiving
reatment, the effect of medication was also difficult to
ssess, as patients often require more than one medication
nd for variable periods of time. Although some earlier
tudies have shown a possible effect of calcium antagonists
n LV remodeling (29), this has not been confirmed in
ore recent larger studies (2,30,31). In this study, no effect
f medication on wall thinning was identified. Randomized
rials in larger populations, to evaluate the possible effects of
edication on cardiac remodeling in HCM, will be wel-
omed. Medication may have led us to underestimate
ertain echocardiographic variables such as LVOTG, al-
hough a significant effect on wall thickness measurements
s unlikely. The natural history of patients studied may also
ave been altered by other interventions such as myectomy
r septal alcohol ablation, and we therefore excluded these
atients from serial evaluation. Patients with pacemakers
nd ICDs, however, were not excluded. The effect of
ntervention on survival of the original study cohort could
ot be established because of a small number of terminal
vents. Finally, the process of wall thinning may relate to
he underlying mutation; however, we are unable to present
his data, as genetic testing was not routinely performed in
he study cohort.
onclusions. Left ventricular remodeling is common in
atients with severe LVH and may account for the low
revalence of severe LVH in middle age and beyond.
emodeling was not associated with an increased sudden
eath risk, but may be associated with increased risk from
ther disease-related complications.
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